MedTrace Logo

Brentuximab Vedotin in Combination With CHEP in Patient With PTCL

NCT05006664 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2021-09-01

No results posted yet for this study

Summary

A Phase II Open Label Study of Brentuximab Vedotin in Combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral T-cell Lymphomas (PTCL)

Conditions

  • Lymphoma, T-Cell, Peripheral

Interventions

DRUG

Adcetris 50 MG Injection

Treatment by study drug Brentuximab Vedotin (Adcetris) in combination with CHEP.

DRUG

Endoxan

Treatment by study drug Cyclophosphamide (Endoxan) in combination.

DRUG

Doxorubicin

Treatment by study drug Doxorubicin in combination.

DRUG

Etoposide

Treatment by study drug Etoposide in combination.

DRUG

Prednisone tablet

Treatment by study drug Prednisone in combination.

Sponsors & Collaborators

  • Czech Lymphoma Study Group

    lead OTHER

Principal Investigators

  • Magdaléna Zikmundová, MD, Ph.D. · Subinvestigator, Protocol completation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-31
Primary Completion
2024-10-31
Completion
2024-10-31

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05006664 on ClinicalTrials.gov